{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:08:01Z","timestamp":1759133281787,"version":"3.41.0"},"reference-count":43,"publisher":"JLE","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.nephro.2017.06.006","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T20:03:47Z","timestamp":1520798627000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["N\u00e9phrotoxicit\u00e9 m\u00e9dicamenteuse"],"prefix":"10.1684","volume":"14","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.06.006_bib0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nephro.2017.06.006_bib0225","unstructured":"The Uppsala monitoring centre. The use of the WHO-UMC system for standardised case causality assessment. From: www.who-umc.org\/media\/2768\/standardised-case-causality-assessment.pdf."},{"key":"10.1016\/j.nephro.2017.06.006_bib0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0272-6386(12)81128-0","article-title":"Community-acquired acute renal failure","volume":"17","author":"Kaufman","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.06.006_bib0235","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/ajkd.2002.32766","article-title":"Hospital-acquired renal insufficiency","volume":"39","author":"Nash","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.06.006_bib0240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1525-1497.2000.04199.x","article-title":"Drug complications in outpatients","volume":"15","author":"Gandhi","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0245","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.ccx.0000184300.68383.95","article-title":"Drug-induced acute kidney injury","volume":"11","author":"Schetz","year":"2005","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.nephro.2017.06.006_bib0250","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","article-title":"Program to improve care in acute renal disease. Spectrum of acute renal failure in the intensive care unit: the PICARD experience","volume":"66","author":"Mehta","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.06.006_bib0255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2017.06.006_bib0260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","article-title":"Biomarkers of acute kidney injury","volume":"48","author":"Vaidya","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0265","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.05191107","article-title":"Diagnosis, epidemiology and outcomes of acute kidney injury","volume":"3","author":"Waikar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0270","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nephro.2017.06.006_bib0275","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.06.006_bib0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","article-title":"Electrolyte disorders associated with the use of anticancer drugs","volume":"777","author":"Liamis","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0285","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00467-014-2958-5","article-title":"Drug-induced acid-base disorders","volume":"30","author":"Kitterer","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0290","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0295","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccc.2015.06.005","article-title":"Drug-induced acute kidney injury: a focus on risk assessment for prevention","volume":"31","author":"Kane-Gill","year":"2015","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.nephro.2017.06.006_bib0300","first-page":"457","article-title":"Drug-induced impairment of renal function","volume":"12","author":"Pazhayattil","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.nephro.2017.06.006_bib0305","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0310","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002800050661","article-title":"Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods","volume":"40","author":"Stewart","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0315","first-page":"37","article-title":"Low serum albumin and the increased risk of amikacin nephrotoxicity","volume":"46","author":"Contreras","year":"1994","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.nephro.2017.06.006_bib0320","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/qjmed\/77.1.1013","article-title":"Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy","volume":"77","author":"Kalra","year":"1990","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0325","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJMra032401","article-title":"Acute renal failure and sepsis","volume":"351","author":"Schrier","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0330","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0022-3565(25)23472-3","article-title":"Augmentation of antibiotic nephrotoxicity by endotoxemia in the rabbit","volume":"234","author":"Tune","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nephro.2017.06.006_bib0335","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1592\/phco.21.5.443.34490","article-title":"Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs","volume":"21","author":"Streetman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nephro.2017.06.006_bib0340","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00002512-199609050-00005","article-title":"Non steroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment","volume":"9","author":"Ailabouni","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1016\/j.nephro.2017.06.006_bib0345","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1525-1497.1998.00224.x","article-title":"Risk factors for toxicity in elderly patients given aminoglycosides once daily","volume":"13","author":"Paterson","year":"1998","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0350","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbarth","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/JDI-100100888","article-title":"Renal involvement in multiple myeloma: a 10-year study","volume":"22","author":"Sakhuja","year":"2000","journal-title":"Ren Fail"},{"key":"10.1016\/j.nephro.2017.06.006_bib0360","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0365","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2017.06.006_bib0370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cccn.2004.09.005","article-title":"Drug-induced renal failure: a focus on tubulointerstitial disease","volume":"351","author":"Markowitz","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nephro.2017.06.006_bib0375","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/106002808101500401","article-title":"Cephalosporin-aminoglycoside synergistic nephrotoxicity: fact or fiction?","volume":"15","author":"Mannion","year":"1981","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.nephro.2017.06.006_bib0380","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nephro.2017.06.006_bib0385","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-002-0867-5","article-title":"Combination of ceftriaxone and acyclovir \u2013\u00a0an underestimated nephrotoxic potential?","volume":"17","author":"Vomiero","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0390","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/qjmed\/95.5.291","article-title":"Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides","volume":"95","author":"Raveh","year":"2002","journal-title":"QJM"},{"key":"10.1016\/j.nephro.2017.06.006_bib0395","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","article-title":"Renal transporters in drug development","volume":"53","author":"Morrissey","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0400","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"International transporter consortium. Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nephro.2017.06.006_bib0405","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.pharmtox.44.101802.121856","article-title":"Transporters and renal drug elimination","volume":"44","author":"Lee","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.nephro.2017.06.006_bib0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients","volume":"10","author":"Khrunin","year":"2010","journal-title":"Pharmacogenomics J"},{"year":"2009","series-title":"Center for drug evaluation and research, US food and drug administration. Review of qualification data for biomarkers of nephrotoxicity submitted by the predictive safety testing consortium","author":"Blank","key":"10.1016\/j.nephro.2017.06.006_bib0415"},{"key":"10.1016\/j.nephro.2017.06.006_bib0420","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tox.2014.05.005","article-title":"Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury","volume":"324","author":"Pavkovic","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.nephro.2017.06.006_bib0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2016.03.016","article-title":"MicroRNAs and drug-induced kidney injury","volume":"163","author":"Pavkovic","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nephro.2017.06.006_bib0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tibtech.2015.11.001","article-title":"Kidney-on-a-chip technology for drug-induced nephrotoxicity screening","volume":"34","author":"Wilmer","year":"2016","journal-title":"Trends Biotechnol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517305953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517305953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.06.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:15:14Z","timestamp":1751480114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517305953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1769725517305953"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.06.006","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phrotoxicit\u00e9 m\u00e9dicamenteuse","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}